New pill aims to wipe out lingering lymphoma cells after remission

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diffuse large B-cell lymphoma, CD20-positive. * Double-expressor lymphoma confirmed by pathology, defined as MYC expression \>=40% and BCL2 expression \>=50% by immunohistochemistry. * Complete response after initial induction therapy. * Age \>=18 and \<=80 years. * ECOG performance status 0-2. * No prior history of malignant tumor and no concurrent malignancy. * International Prognostic Index (IPI) score \>1. * ctDNA MRD-positive at screening/enrollment. * Life expectancy of at least 6 months, in the opinion of the investigator. * Written informed consent provided before any study-specific procedure. Exclusion Criteria: * Failure to achieve complete response after initial induction therapy. * Prior organ transplantation. * Uncontrolled coagulopathy or active bleeding. * Uncontrolled cardiovascular or cerebrovascular disease, including left ventricular ejection fraction \<50%, connective tissue disease, or severe active infection. * Major organ surgery within 6 weeks before screening. * Screening laboratory abnormalities not attributable to lymphoma, including: neutrophil count \<1.5 x 10\^9/L; platelet count \<80 x 10\^9/L (or \<50 x 10\^9/L in patients with bone marrow involvement); total bilirubin \>1.5 x upper limit of normal; ALT/AST \>2.5 x upper limit of normal, or \>5 x upper limit of normal in patients with hepatic involvement; serum creatinine \>1.5 x upper limit of normal. * Active hepatitis B not meeting protocol-defined virologic criteria for enrollment; patients with positive HBsAg or positive HBcAb require HBV DNA testing and must meet protocol-specified thresholds. * HIV infection. * Ongoing antitumor therapy for lymphoma or another malignancy. * Drug abuse or chronic alcohol abuse that may interfere with study evaluation. * Psychiatric illness or any condition resulting in inability to comply with the protocol. * Requirement for ongoing treatment with strong or moderate CYP3A inhibitors or inducers; patients exposed to these agents within 7 days before first study dose, or within fewer than 5 half-lives, are not eligible. * Inability to swallow capsules or clinically significant gastrointestinal disorders that may affect drug absorption, including malabsorption syndrome, bariatric surgery, inflammatory bowel disease, or partial/complete bowel obstruction. * Any other uncontrolled medical condition that, in the investigator's judgment, may compromise safety, interfere with oral drug absorption or metabolism, or place the participant at excessive risk.